RNXT — RenovoRx, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1574094 ·
Last close
$0.96
Market Cap
$43.20M
52W High
$1.00
52W Low
$0.77
ADV30
220,997
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 563,000 | 479,000 | -3,469,000 | -3,521,000 | 13,964,000 | 12,362,000 | 2,699,000 |
| Dec 2025 | 238,000 | 210,000 | -3,523,000 | -2,941,000 | 8,095,000 | 7,024,000 | 2,673,000 |
| Sep 2025 | 266,000 | 213,000 | -3,200,000 | -2,912,000 | 11,206,000 | 10,044,000 | 3,128,000 |
| Jun 2025 | 422,000 | 270,000 | -2,678,000 | -2,895,000 | 13,643,000 | 12,314,000 | 3,002,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-11,301,000
Investing CF
$0
Financing CF
$9,081,000
CapEx
$-2,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.33
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-64,908,000
Inventory
$379,000
Receivables
$280,000
ST Investments
—
EBIT TTM
$-12,870,000
Pretax Income TTM
$-12,270,000
Interest Exp TTM
—
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,489,000
EBITDA
$-12,367,000
Free Cash Flow
$-6,454,625
Enterprise Value
$31,042,500
Total Cash
$12,362,000
Total Debt
$186,000
Shares Out
45,099,133
Trailing EPS
$-0.33
Book Value
$0.25
ROE
-100.5%
ROA
-51.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 1,123,000 | -12,511,000 | -11,168,000 | 8,095,000 | 2,673,000 | — | -10,973,000 |
| Dec 2024 | 43,000 | -10,970,000 | -8,814,000 | 8,118,000 | 3,640,000 | — | -9,125,000 |
| Dec 2023 | 0 | -11,396,000 | -10,232,000 | 1,466,000 | 4,466,000 | — | -10,258,000 |
| Dec 2022 | 0 | -9,950,000 | -9,889,000 | 7,265,000 | 1,102,000 | — | -8,811,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.15
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| KPTI | Karyopharm Therapeutics Inc. | $43.51M | $1.92 | — |
| CPHI | CHINA PHARMA HOLDINGS, INC. | $44.98M | $1.11 | — |
| IBO | IMPACT BIOMEDICAL INC. | $46.36M | $0.43 | — |
| HYPD | HYPERION DEFI, INC. | $40.02M | $2.64 | — |
| MCRB | Seres Therapeutics, Inc. | $46.77M | $4.83 | — |
News headlines (Yahoo Finance, 1h cache)
RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET
2026-07-29 12:30 · Yahoo
iAccess Alpha Virtual Best Ideas Summer Investment Conference Begins Today
2026-06-23 12:15 · Yahoo
iAccess Alpha's Virtual Best Ideas Summer Investment Conference June 23–24, 2026
2026-06-18 13:00 · Yahoo
RenovoRx Highlights Peer-Reviewed Publication Supporting Intra-Arterial Gemcitabine Delivery Via TAMP™ in Locally Advanced Pancreatic Cancer
2026-06-11 12:30 · Yahoo
RenovoRx CEO, Shaun Bagai, to Present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 on June 23rd
2026-06-04 12:30 · Yahoo
RenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic Cancer
2026-05-28 12:30 · Yahoo
RenovoRx Announces Promising Pharmacokinetic Data Using the TAMP™ Platform Presented at the 2026 ASCO Annual Meeting
2026-05-26 12:30 · Yahoo
RenovoRx to Present at the Alliance Global Partners Virtual Annual Healthcare Company Showcase on May 20th
2026-05-19 12:30 · Yahoo
RenovoRx, Inc. Q1 2026 Earnings Call Summary
2026-05-15 12:30 · Yahoo
RenovoRx Inc (RNXT) Q1 2026 Earnings Call Highlights: Record Revenue and Strategic Expansion
2026-05-15 05:01 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.